Komori
Changes in Officers2160GNI Group Ltd.Pharmaceuticals

Notice Regarding Changes in Executive Officers

Zhang Ping (張平), a director and executive officer, will newly assume responsibility for CBDO (Chief Business Development Officer), and Kawaraya Toshitaka (瓦谷俊隆) has been appointed from outside the company as executive officer and Head of Business Development.

Worth reading
35Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Who is moving to which position

Resolved 4 September 2026

Incoming appointee

1 item
Scheduled Appointment Date4 September 2026
Kawaraya Toshitaka (瓦谷俊隆)
Previous positionPartner, Consulting and Navigation Unit, シミックホールディングス株式会社
New positionExecutive Officer, Head of Business Development
入社年 2026
Reason for change

To newly appoint a CBDO to oversee business development and synergy creation across the group, welcome Kawaraya Toshitaka (瓦谷俊隆) as Head of Business Development, and promote collaboration with group companies in Japan and overseas, the exploration of new business opportunities, partnerships with external companies, and product introductions.

Details of organizational changes

A CBDO will be newly appointed, and a Head of Business Development position will be established.

Who is moving to which position
ItemDetails
Resolution date4 September 2026
Scheduled Appointment Date4 September 2026
Name of appointeeKawaraya Toshitaka (瓦谷俊隆)
Appointee's new positionExecutive Officer, Head of Business Development
Appointee's previous positionPartner, Consulting and Navigation Unit, シミックホールディングス株式会社
Year the appointee joined the Company2026
Reason for changeTo newly appoint a CBDO to oversee business development and synergy creation across the group, welcome Kawaraya Toshitaka (瓦谷俊隆) as Head of Business Development, and promote collaboration with group companies in Japan and overseas, the exploration of new business opportunities, partnerships with external companies, and product introductions.
Details of organizational changesA CBDO will be newly appointed, and a Head of Business Development position will be established.
Items this document does not state (13)
Date of departureAppointee's date of birthNumber of shares held by the appointeeName of departing officerFormer position of departing officerNew position of departing officerReason for departureWhether the incumbent will remain in officeReasons for appointmentNumber of directors after the changeFiling as an independent officerChange in Corporate Governance StructureSubject to Approval by the General Meeting of Shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Following the full acquisition of Cullgen Inc. by a consolidated subsidiary and the acquisition of all shares in あゆみ製薬ホールディングス株式会社, the company will promote business development and create synergies aimed at becoming a global biopharma company. It will advance collaboration with group companies in Japan and overseas, explore new business opportunities, pursue partnerships with external companies, and introduce products.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Changes in Executive Officers | GNI Group Ltd. (2160) timely disclosure | Komori